The firm successfully completed NASDAQ listing in 2017, in just three years after its inception. Today, it has two marketed products, nine late-stage clinical assets with more than 20 indications and 25 ongoing and planned trials. In an email interaction with BioSpectrum Asia, Dr Samantha Du shares with us about her company, milestones, achievements and the ongoing coronavirus crisis’ impact on the biopharma business.
Can you give us an overview of Zai Lab?
Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company with seven offices located in China, United States and Hong Kong, focused on bringing transformative medicines to patients suffering from cancer, autoimmune and infectious diseases to patients in China and around the world.
Over the next three years, we aim to be one of the leading biopharma companies on the global stage. Since our inception in 2014, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad and diverse pipeline of innovative drug candidates. We have also established our own manufacturing facilities and a highly specialized commercial team to support marketing of our innovative products in China. We believe our integrated approach will provide sustainable competitive advantages for Zai Lab. We have built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.
We successfully listed on the Nasdaq Stock Exchange in September 2017 when we had four clinical-stage assets. Today, we have two marketed products, nine late-stage clinical assets with more than 20 indications and 25 ongoing and planned trials. As of April 2019, the company has a global team of over 800 employees.
This story is from the July 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the July 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
